Here are the DEF 14A proxy statements from PURE Bioscience (PURE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow PURE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PURE filings page.
PURE Bioscience, Inc. has called its 2026 annual stockholder meeting for February 17, 2026 at 10:30 a.m. local time in Huntington Beach, California. Stockholders of record as of December 22, 2025, when 111,886,485 shares of common stock were outstanding, will vote on four key items.
They are being asked to elect seven directors, ratify Weinberg & Company, P.A. as independent auditor for the fiscal year ending July 31, 2026, approve on an advisory basis the compensation of named executive officers, and approve an amendment to the Certificate of Incorporation to increase authorized common shares from 200,000,000 to 250,000,000. As of December 22, 2025, a total of 176,722,446 shares were outstanding or reserved under options, RSUs, convertible debt and the 2024 Equity Incentive Plan, so the additional authorization is intended to provide flexibility for future financings, equity compensation and other corporate purposes. The Board recommends voting in favor of all proposals.